These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

148 related items for PubMed ID: 1337810

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2. Effectiveness of short-course therapy (5 days) with cefuroxime axetil in treatment of secondary bacterial infections of acute bronchitis.
    Henry D, Ruoff GE, Rhudy J, Puopolo A, Drehobl M, Schoenberger J, Giguere G, Collins JJ.
    Antimicrob Agents Chemother; 1995 Nov; 39(11):2528-34. PubMed ID: 8585739
    [Abstract] [Full Text] [Related]

  • 3. Cefprozil. A review of its antibacterial activity, pharmacokinetic properties, and therapeutic potential.
    Wiseman LR, Benfield P.
    Drugs; 1993 Feb; 45(2):295-317. PubMed ID: 7681376
    [Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5. Efficacy and safety of cefprozil versus other beta-lactam antibiotics in the treatment of lower respiratory tract infections.
    Ball P.
    Eur J Clin Microbiol Infect Dis; 1994 Oct; 13(10):851-6. PubMed ID: 7889959
    [Abstract] [Full Text] [Related]

  • 6. Comparison of oral cefuroxime axetil and oral amoxycillin/clavulanate in the treatment of community-acquired pneumonia.
    Higuera F, Hidalgo H, Feris J, Giguere G, Collins JJ.
    J Antimicrob Chemother; 1996 Mar; 37(3):555-64. PubMed ID: 9182112
    [Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8. Review of the spectrum and potency of orally administered cephalosporins and amoxicillin/clavulanate.
    Sader HS, Jacobs MR, Fritsche TR.
    Diagn Microbiol Infect Dis; 2007 Mar; 57(3 Suppl):5S-12S. PubMed ID: 17292577
    [Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10. Cefuroxime axetil: an updated review of its use in the management of bacterial infections.
    Scott LJ, Ormrod D, Goa KL.
    Drugs; 2001 Mar; 61(10):1455-500. PubMed ID: 11558834
    [Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12. A comparison of the efficacy and safety of cefuroxime axetil and augmentin in the treatment of upper respiratory tract infections.
    Hebblethwaite EM, Brown GW, Cox DM.
    Drugs Exp Clin Res; 1987 Mar; 13(2):91-4. PubMed ID: 3582135
    [Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17. Blinded comparison of cefuroxime to cefaclor for lower respiratory tract infections.
    Schleupner CJ, Anthony WC, Tan J, File TM, Lifland P, Craig W, Vogelman B.
    Arch Intern Med; 1988 Feb; 148(2):343-8. PubMed ID: 3277562
    [Abstract] [Full Text] [Related]

  • 18. Therapy with newer oral beta-lactam and quinolone agents for infections of the skin and skin structures: a review.
    Gentry LO.
    Clin Infect Dis; 1992 Jan; 14(1):285-97. PubMed ID: 1571443
    [Abstract] [Full Text] [Related]

  • 19. Cefuroxime axetil. A review of its antibacterial activity, pharmacokinetic properties and therapeutic efficacy.
    Perry CM, Brogden RN.
    Drugs; 1996 Jul; 52(1):125-58. PubMed ID: 8799689
    [Abstract] [Full Text] [Related]

  • 20. Clinical comparison of cefuroxime axetil, cephalexin and cefadroxil in the treatment of patients with primary infections of the skin or skin structures.
    Gooch WM, Kaminester L, Cole GW, Binder R, Morman MR, Swinehart JM, Wisniewski M, Yilmaz HM, Collins JJ.
    Dermatologica; 1991 Jul; 183(1):36-43. PubMed ID: 1769413
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 8.